SomaLogic Collaborates with the US FDA to Advance Biosimilar Development
Shots:
- SomaLogic collaborate with the FDA to identify circulating pharmacodynamic biomarkers and analytical approaches that could be used to demonstrate bio-similarity of biosimilar to a reference FDA-approved biologic drug
- The collaboration will utilize the SomaLogic proteomic technology for the identification of circulating pharmacodynamic biomarkers for therapeutic biologics
- SomaLogic’s SomaScan platform makes 5-000 protein measurements simultaneously in small samples of blood- to compare changes in circulating proteins following treatment with FDA-approved biologics and could reduce the need for costly and lengthy comparative clinical studies
Ref: GlobeNewswire | Image: SomaLogic
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com